Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | Director | December 07, 2012 | December 07, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date December 07, 2012 · Filed December 07, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2012-12-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date February 28, 2013 · Filed March 02, 2013
Section 16 reporting ended · disclosed 2013-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 137,475 |
Reported balance
After 2013-02-28 transaction · row 1
1 source rowRow 1 · 2013-02-28 · Tax withholding · Disposed 9,188 · Balance 137,475 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 4,134 |
Reported balance
Holding disclosure · report date 2013-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,134 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2013.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $51.08 | $25,540.00 |
DisclosureSEC source: 0001104659-11-023803 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,877 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $51.06 | $10,212.00 |
DisclosureSEC source: 0001104659-11-023803 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,377 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,000 | $51.41 | $514,057.00 |
DisclosureSEC source: 0001104659-11-023804 · a4.xml · nonDerivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Profit Sharing Trust Disclosed balance after: 3,791 F1 · balance_after: Balance in the Abbott Laboratories Stock Retirement Trust as of April 26, 2011. Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $51.37 | $5,137.00 |
DisclosureSEC source: 0001104659-11-023804 · a4.xml · nonDerivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,577 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $51.36 | $10,272.00 |
DisclosureSEC source: 0001104659-11-023804 · a4.xml · nonDerivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,677 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $51.35 | $20,540.00 |
DisclosureSEC source: 0001104659-11-023804 · a4.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,877 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $51.34 | $10,268.00 |
DisclosureSEC source: 0001104659-11-023804 · a4.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,277 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $51.34 | $5,133.50 |
DisclosureSEC source: 0001104659-11-023804 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,477 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $51.33 | $15,399.00 |
DisclosureSEC source: 0001104659-11-023804 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,577 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $47.92 | $14,376.30 |
DisclosureSEC source: 0001179110-11-003913 · edgar.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,577 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $47.92 | $4,792.08 |
DisclosureSEC source: 0001179110-11-003913 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,877 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 688 | $47.92 | $32,971.02 |
DisclosureSEC source: 0001179110-11-003913 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,977 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,297 | $47.64 | $299,989.08 |
DisclosureSEC source: 0001179110-11-003913 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,665 Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 28,200 | $0.00 Strike: $46.60 | $0.00 |
DisclosureSEC source: 0001179110-11-003276 · edgar.xml · derivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,200 Underlying: Common shares · 28,200 shares Expires 2021-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,400 on 02/18/2012, 9,400 on 02/18/2013, and 9,400 on 02/18/2014. Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-003276 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,962 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 08, 2011 Filed Feb 10, 2011 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,200 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001179110-11-002411 · edgar.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,200 shares Expires 2011-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 08, 2011 Filed Feb 10, 2011 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $45.55 | $4,555.25 |
DisclosureSEC source: 0001179110-11-002411 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,862 Read SEC document |
| February 08, 2011 Filed Feb 10, 2011 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $45.46 | $95,455.71 |
DisclosureSEC source: 0001179110-11-002411 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,962 Read SEC document |
| February 08, 2011 Filed Feb 10, 2011 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,200 | $45.45 | $99,987.36 |
DisclosureSEC source: 0001179110-11-002411 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $49.79 | $4,979.00 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 14 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,862 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $49.78 | $39,824.00 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 13 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,962 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $49.78 | $4,977.50 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 12 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,762 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $49.77 | $59,724.00 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 11 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,862 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $49.77 | $9,953.00 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 10 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,062 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $49.76 | $29,856.00 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 9 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,262 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,389 | $49.72 | $218,221.08 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 8 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,862 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $49.72 | $79,544.00 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,251 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,439 | $49.71 | $419,502.69 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,851 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,067 | $49.70 | $351,229.90 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,290 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $49.70 | $4,969.50 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,357 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,344 | $49.66 | $166,063.04 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,457 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,705 | $49.65 | $84,653.25 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,801 Read SEC document |
| August 02, 2010 Filed Aug 3, 2010 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 356 | $49.64 | $17,671.84 |
DisclosureSEC source: 0001179110-10-012160 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,506 Read SEC document |
| February 26, 2010 Filed Mar 2, 2010 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,603 | $54.12 | $303,234.36 |
DisclosureSEC source: 0001179110-10-004245 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,862 Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value · Derivative | 28,700 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001179110-10-003578 · edgar.xml · derivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Underlying: Common Shares · 28,700 shares Expires 2020-02-18 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,567 on 02/19/2011, 9,566 on 02/19/2012, and 9,567 on 02/19/2013. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003578 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,465 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2010 Filed Feb 24, 2010 01:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-003578 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,465 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $53.92 | $75,490.80 |
DisclosureSEC source: 0001179110-10-003157 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,865 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $53.92 | $5,392.22 |
DisclosureSEC source: 0001179110-10-003157 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,265 Read SEC document |
| February 16, 2010 Filed Feb 18, 2010 23:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,473 | $53.93 | $241,228.89 |
DisclosureSEC source: 0001179110-10-003157 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,365 Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 18,744 | $0.00 Strike: $52.55 | $0.00 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · derivative · entry 11 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,744 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,564 | $0.00 Strike: $48.72 | $0.00 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · derivative · entry 10 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,564 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $54.16 | $102,904.00 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 8 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,838 Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,200 | $54.15 | $281,580.00 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,738 Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,108 | $54.14 | $547,247.12 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,938 Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,500 | $54.13 | $351,845.00 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,046 Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,800 | $54.12 | $313,896.00 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,546 Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $54.11 | $43,288.00 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,346 Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 18,744 | $52.55 | $984,997.20 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2009 Filed Dec 24, 2009 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,564 | $48.72 | $563,389.99 |
DisclosureSEC source: 0001179110-09-017415 · edgar.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.